STADA Group said it has acquired the existing distribution and sales of Nizoral Cream - an antifungal drug - in the markets of Vietnam, the Philippines and Thailand as well as the trademark (TM) rights in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore.
 |
| STADA expands business in Asia- Pacific . |
STADA Pharmaceutical Group announced on August 19 that it is expanding its Consumer Healthcare business in the Asia- Pacific region through the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson. The product contains the active ingredient ketoconazole, which is indicated for the treatment of dermatophytosis.
Under the terms of the agreement, STADA has acquired Nizoral Cream's existing distribution and sales business in the markets of Vietnam, the Philippines and Thailand as well as the trademark (TM) rights in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore.
This is an extension of STADA's previous acquisition of the brand in the Asia-Pacific region.
Previously, in 2018, STADA successfully acquired the Nizoral brand in key markets in Europe, the Middle East and Africa.
Mr. Stephane Jacqmin, Executive Vice President in charge of emerging markets of STADA Group, said that the above event aims to expand the market in the Asia-Pacific region.
In particular, Stada Arzneimittel AG Pharmaceutical Group is headquartered in Bad Vilbel, Germany, focusing on consumer healthcare products, generics and specialty pharmaceuticals.
In 2023, STADA's total revenue reached EUR 3,734.8 million and earnings before interest, taxes, depreciation and amortization reached EUR 802.1 million. As of December 31, 2023, STADA had 11,667 employees worldwide .
Source: https://baodautu.vn/stada-thau-tom-thuong-hieu-nizoral-cream-tai-viet-nam-d222758.html
Comment (0)